Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research report issued on Friday. The firm set a “sell” rating on the stock.

Oragenics Stock Up 12.5 %

NYSE:OGEN opened at $0.36 on Friday. Oragenics has a 52 week low of $0.25 and a 52 week high of $7.74. The firm has a 50 day moving average of $0.33 and a 200 day moving average of $0.92. The stock has a market capitalization of $4.40 million, a price-to-earnings ratio of -0.05 and a beta of 0.43.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new stake in shares of Oragenics, Inc. (NYSE:OGEN) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics at the end of the most recent quarter. 18.71% of the stock is owned by institutional investors.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.